Document Detail

Thrombin activatable fibrinolysis inhibitor (TAFI): relationship to hemostatic alteration in patients with beta-thalassemia.
MedLine Citation:
PMID:  20670166     Owner:  NLM     Status:  MEDLINE    
Profound hemostatic changes have been observed among thalassemic patients. Thrombin activatable fibrinolysis inhibitor (TAFI) is a newly discovered protein that potentially attenuates fibrinolysis. The authors aimed to investigate plasma level of TAFI in beta-thalassemia patients in relation to clinical severity and hemostatic alteration. Fifty-one thalassemic patients (mean age 10.79 +/- 5.59 years) (21 splenectomized thalassemia major patients, 18 nonsplenectomized thalassemia major patients, 12 nonsplenectomized thalassemia intermedia) were recruited from Pediatric Hematology Clinic, Ain Shams University; in addition, 32 healthy age- and sex-matched controls (10.31 +/- 5.58 years) were also included. In addition to clinical assessment, laboratory investigations included complete blood count (CBC), hemoglobin electrophoresis, prothrombin time (PT), activated partial thromboplastin time (PTT), liver function tests, viral hepatitis markers, serum ferritin, and plasma TAFI levels. Nine out of 51 patients (17.5%) suffered from bleeding manifestations mainly in the form of epistaxis; none of the studied patients had thromboembolism. Significant reduction in TAFI levels was shown in thalassemic patients compared to controls (P < .0001), in splenectomized compared to nonsplenectomized thalassemia group (P < .0001), and in thalassemia major compared to thalassemia intermedia group (P < .0001). Negative correlation was present between TAFI levels and both liver enzymes and serum ferritin levels (P < .05). Thalassemic patients suffering from bleeding showed lower mean TAFI levels compared to those not suffering from bleeding (P < .001). Marked reduction in TAFI levels was observed in thalassemic patients with splenectomy, altered liver functions, and poor chelation who therefore might be at a higher risk for altered hemostasis.
Galila M Mokhtar; Randa M Matter; H Shawki; Manal M Abdel Aziz
Related Documents :
8948666 - Factitious sickle cell acute painful episodes: a secondary type of munchausen syndrome.
1765296 - Relationship between peripheral vascular closure and proliferative retinopathy in sickl...
20001626 - Fetal globin induction in beta-thalassemia.
11158406 - Normalization of haemoglobin concentration with recombinant erythropoietin has minimal ...
11526366 - Carvedilol titration in patients with congestive heart failure receiving inotropic ther...
21505266 - Multi-center study on the prevalence of hypothyroidism in patients with hypercholestero...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pediatric hematology and oncology     Volume:  27     ISSN:  1521-0669     ISO Abbreviation:  Pediatr Hematol Oncol     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-30     Completed Date:  2010-12-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8700164     Medline TA:  Pediatr Hematol Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  363-73     Citation Subset:  IM    
Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Carboxypeptidase U / blood*
Case-Control Studies
Child, Preschool
Clinical Enzyme Tests
Ferritins / blood
Liver / enzymology
Liver Function Tests
Severity of Illness Index
beta-Thalassemia / blood*,  diagnosis
Reg. No./Substance:
9007-73-2/Ferritins; EC U

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Myelofibrosis in children: experience at a single tertiary care center in India.
Next Document:  A report of 8 cases with hemoglobin H disease in an Iranian family.